Pathological retinal/choroidal neovascularization drives vision loss in DR and AMD. Current anti-VEGF injections, while effective, require invasive, frequent administration. Pene/LQ015, is developed a novel topical anti-VEGFA nanobody formulation achieving therapeutic intraocular levels through penetratin analog-enhanced delivery. Preclinical studies in primate CNV models showed significant neovascularization suppression with safety, positioning this noninvasive treatment as a paradigm-shifting alternative for fundus angiogenesis diseases. Abstract Pathological retinal and choroidal neovascularization is a hallmark of several blinding diseases, including diabetic retinopathy and age-related macular degeneration. While intravitreal anti-VEGF therapies remain the standard of care, they necessitate frequent injections, posing risks such as endophthalmitis and elevated intraocular pressure, alongside economic and adherence challenges. Here, we present Pene/LQ015, a novel eye drop formulation comprising the anti-VEGFA nanobody (LQ015) and a proprietary penetratin analog for noninvasive delivery. LQ015 demonstrates superior VEGF-blocking activity, broad binding specificity across species, and robust stability and scalability using a yeast expression system. Topical administration of Pene/LQ015 achieved effective retinal-choroid complex drug levels and suppressed neovascularization in preclinical models. Notably, in the cynomolgus monkey laser-induced choroidal neovascularization model, 30 days of continuous topical application significantly reduced neovascularization and vascular leakage, with excellent safety and tolerability. These findings highlight Pene/LQ015's potential as a game-changer in treating neovascular eye diseases. It offers a groundbreaking, noninvasive alternative to intravitreal injections, addressing key limitations of current therapies by enabling continuous dosing, improving patient adherence, and reducing treatment burden. These findings underscore its potential to transform the management of neovascular retinal and choroidal diseases, with promising implications for clinical application.

GNQWFI is a GMP-grade anti-Flt1 hexapeptide (VEGFR1-specific antagonist) with 99.45% purity. It blocks VEGFR1 interactions with VEGFA/VEGFB/PlGF and inhibits VEGF-induced endothelial migration and tube formation. Available for wholesale and retail. For laboratory research use only.（For wholesale prices, other specifications and uses, please consult our staff）

Metastasis remains a primary contributor to cancer-related mortality. Elevated expression of soluble vascular endothelial growth factor A (VEGFA) isoforms is linked to increased metastatic potential a...